Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer
Authors:
- Pamela AllenPAPamela Allen
- Andrew McBrideAMAndrew McBride
- Thomas BuchholzTBThomas Buchholz
- Aysegul SahinASAysegul Sahin
- 13 March 2015
- journal article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 139 (10) , 1288-1294
Abstract
Context: Lymph node status and the number of lymph node (LN) positive for cancer cells are the most important prognostic factors in breast cancer. Extranodal tumor extension (ENTE) has been used as a histopathologic feature to classify patients into high risk versus low risk for local recurrence. However, in the current era of early detection and systemic therapy, the prognostic significance of ENTE is not as well defined in patients with 1 to 3 LNs positive for cancer. Objective: To determine whether the amount of tumor burden in an axillary dissection or the presence of ENTE provides any additional information regarding patient outcome in patents with 1 to 3 positive LN results. Design: Clinical and pathologic factors were identified for 456 patients with breast cancer at the University of Texas MD Anderson Cancer Center, Houston, who had pT1 tumors and 1 to 3 LNs positive for cancer and were treated by mastectomy, with or without postmastectomy radiotherapy, between 1978 and 2007. Results: Of the 456 patients, 257 (56.4%), 141 (31.6%), and 58 (12.7%) patients had 1, 2, or 3 positive LN results, respectively. Extranodal tumor extension was present in 99 patients (21.7%) and was absent in the remaining 357 cases (78.3%). Seventy-six patients (16.7%) received radiation therapy. Patients had both worse overall survival time and disease-free survival when ENTE was present, regardless of the amount, as long as the treatment era was not included in the multivariate analysis (pre-2000 versus post-2000). However, ENTE was no longer significant on multivariate analysis when the year of treatment was taken into account. Conclusions: The number of positive LNs remains an important predictor of survival in patients with 1 to 3 positive LN results, but the prognostic significance of ENTE in this cohort of patients has diminished over time.Keywords
This publication has 40 references indexed in Scilit:
- Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic TreatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Risk Factors for Locoregional Recurrence Among Breast Cancer Patients: Results From International Breast Cancer Study Group Trials I Through VIIJournal of Clinical Oncology, 2003
- The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 2000
- Consensus statement on postmastectomy radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 1999
- Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast CancerNew England Journal of Medicine, 1997
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant ChemotherapyNew England Journal of Medicine, 1997
- Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy.Journal of Clinical Oncology, 1988